Serotonin (5 Hydroxytryptamine, 5 Ht) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Serotonin, also known as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter derived from the amino acid tryptophan that modulates a vast array of physiological and behavioral processes, including mood, cognition, sleep, appetite, pain perception, and neuroendocrine function. In the central nervous system, serotonergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- are concentrated in the raphe nuclei of the brainstem, from which they project diffusely throughout the brain, including the [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--, [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, and [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- [1].
Serotonergic dysfunction is a prominent feature of multiple [neurodegenerative diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. In [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, early degeneration of the raphe nuclei and depletion of serotonin contribute to depression, sleep disturbances, circadian disruption, and cognitive decline. In [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, serotonergic pathology is implicated in non-motor symptoms including depression, anxiety, psychosis, and levodopa-induced dyskinesias. Emerging evidence positions the serotonergic system as a promising therapeutic target across neurodegenerative conditions [2].
Serotonin is synthesized from the essential amino acid L-tryptophan through a two-step enzymatic process:
Tryptophan hydroxylase (TPH): Converts L-tryptophan to 5-hydroxytryptophan (5-HTP). Two isoforms exist: TPH1 (peripheral, gut and pineal gland) and TPH2 (central, raphe nuclei). TPH2 is the rate-limiting enzyme for brain serotonin synthesis and requires tetrahydrobiopterin (BH4) and molecular oxygen as cofactors.
Aromatic L-amino acid decarboxylase (AADC): Converts 5-HTP to serotonin (5-HT). This is the same enzyme involved in [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- synthesis, requiring pyridoxal phosphate (vitamin B6) as a cofactor.
Notably, serotonin does not cross the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--, so CNS and peripheral serotonin pools are functionally independent. Approximately 95% of total body serotonin resides in the gastrointestinal tract, where it is produced by enterochromaffin cells—a connection highly relevant to [Gut-Brain Axis[/entities/[gut-brain-axis[/entities/[gut-brain-axis[/entities/[gut-brain-axis--TEMP--/entities)--FIX-- signaling in neurodegeneration.
After synthesis, serotonin is transported into synaptic vesicles by vesicular monoamine transporter 2 (VMAT2/SLC18A2). Upon neuronal depolarization, 5-HT is released into the synaptic cleft by calcium-dependent exocytosis.
Serotonin signaling is terminated primarily by the serotonin transporter (SERT/SLC6A4), which mediates reuptake of 5-HT from the synaptic cleft into the presynaptic terminal. SERT is the principal target of selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressants.
Intracellular serotonin is degraded by monoamine oxidase A (MAO-A) to 5-hydroxyindoleacetaldehyde, which is further oxidized by aldehyde dehydrogenase to 5-hydroxyindoleacetic acid (5-HIAA), the primary serotonin metabolite. 5-HIAA levels in cerebrospinal fluid (CSF) serve as a biomarker of central serotonergic activity and are consistently reduced in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- patients [3].
In the pineal gland, serotonin serves as the precursor for melatonin synthesis through sequential N-acetylation (by AANAT) and O-methylation (by ASMT). This serotonin-melatonin pathway is critical for circadian rhythm regulation and is severely disrupted in AD, contributing to sundowning behavior and sleep-wake cycle disturbances.
The serotonin receptor system is the most complex of any neurotransmitter, comprising 7 families (5-HT1 to 5-HT7) and at least 14 receptor subtypes. All are G protein-coupled receptors except 5-HT3, which is a ligand-gated ion channel.
The only ionotropic serotonin receptor; mediates fast excitatory neurotransmission. Expressed on GABAergic interneurons and [vagus nerve] afferents. 5-HT3 antagonists (ondansetron) have shown modest procognitive effects in preclinical AD models.
Expressed in [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and gastrointestinal tract. 5-HT4 receptor activation promotes non-amyloidogenic processing of [APP[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--
Expressed exclusively in the CNS, primarily in striatum, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--. 5-HT6 receptor antagonists (idalopirdine, intepirdine) enhance [acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine[/entities/[acetylcholine--TEMP--/entities)--FIX--, [glutamate[/entities/[glutamate[/entities/[glutamate[/entities/[glutamate--TEMP--/entities)--FIX--, and [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- release and have been extensively investigated as cognitive enhancers in AD. Despite promising preclinical data, Phase III clinical trials have not met primary endpoints, though the pharmacological rationale remains sound [6].
Involved in circadian rhythm regulation, thermoregulation, and memory. Expressed in [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, and hypothalamus. 5-HT7 receptor modulation may address circadian disturbances in AD.
Serotonergic dysfunction is a consistent finding in AD, with multiple lines of evidence:
Raphe Nuclei Degeneration: The dorsal and median raphe nuclei show neuronal loss and tau] pathology early in AD progression (Braak stages I–II), even before neocortical involvement. This produces widespread serotonin depletion across cortical and subcortical targets [1].
Reduced Serotonin and Metabolites: Postmortem AD brains show 40–70% reductions in serotonin and 5-HIAA levels in [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, and CSF. SERT binding is also reduced, reflecting loss of serotonergic terminals.
Circadian and Glymphatic Disruption: Serotonin depletion impairs circadian rhythm regulation and the [glymphatic system[/entities/[glymphatic-system[/entities/[glymphatic-system[/entities/[glymphatic-system--TEMP--/entities)--FIX--, reducing [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- clearance during [sleep] and potentially accelerating disease progression [2].
[Amyloid] Interaction: Serotonin signaling through 5-HT4 receptors promotes non-amyloidogenic [APP[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX--**: Surviving serotonergic terminals aberrantly convert levodopa to [dopamine[/entities/[dopamine[/entities/[dopamine[/entities/[dopamine--TEMP--/entities)--FIX-- and release it without proper feedback regulation, producing pulsatile dopamine surges that cause dyskinesias [9].
Emerging evidence links serotonergic dysfunction to [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--:
[FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- patients show serotonergic deficits contributing to behavioral disinhibition, apathy, dietary changes, and compulsive behaviors. SSRI treatment is first-line pharmacotherapy for behavioral symptoms of FTD.
The study of Serotonin (5 Hydroxytryptamine, 5 Ht) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.